Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PTAFR | P25105 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323527 | 0.96 | CYP4F2 (0.44) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL2763050 | 0.95 | CYP4F2 (0.43) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL17049467 | 0.95 | CYP4F2 (0.43) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL17049469 | 0.95 | CYP4F2 (0.43) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL13324058 | 0.93 | HPGD (0.46) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL13376361 | 0.88 | CYP4F2 (0.41) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL2632341 | 0.86 | HPGD (0.50) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL13324059 | 0.85 | CYP4F2 (0.55) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL13323521 | 0.84 | SMN1; SMN2 (0.46) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 | |
| SCHEMBL13324060 | 0.84 | CYP4F2 (0.49) | HPGDCYP4F2CYP4A11ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682924-B2 | Crystalline form of VSN16 | CANBEX THERAPEUTICS LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20150353476-A1 | CRYSTALLINE FORM OF VSN16 | ULC BUSINESS PLC (GB) | 2015-12-10 | — | — | US | disclosed |
| US-8293796-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114062-A1 | Modulator | CHRNA3, CHRM3, NR3C2 | HPGD 2698/4885CYP4F2 380/4885CYP4A11 279/4885 |
| US-20150353476-A1 | CRYSTALLINE FORM OF VSN16 | VAC14, SFXN1, VIL1 | HPGD 3150/4885CYP4F2 913/4885CYP4A11 1012/4885 |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | CPT1B, MUSK, C1R | HPGD 2246/4885CYP4F2 523/4885CYP4A11 566/4885 |
| US-20100144876-A1 | MODULATOR | CHRNA3, CHRM3, NR3C2 | HPGD 2698/4885CYP4F2 380/4885CYP4A11 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.